American Peptide Company Expands Business Development Team to Serve Growing Customer Base
News Jun 24, 2009
American Peptide Company has announced the appointment of Firuz Shakoori as Sales Director, who has been responsible for new business development since January 2009.
This appointment reflects American Peptide Company’s continued dedication to providing high quality peptides and peptide-based services to support a growing base of pharmaceutical, biotech, and life science customers.
Mr. Shakoori will work closely with customers as their drug products move from discovery to development and commercialization. In this role, he will be responsible for executing the company’s Total Peptide Management program, a customized service platform.
The program has been designed by the company to offer a broad portfolio of peptides, value-added services, and expert consultancy to help the pharmaceutical and life science industries bring new drugs to market faster.
“I’m very enthusiastic about joining the American Peptide Company team at this exciting time in the industry,” says Shakoori. “Innovative peptide-based applications in cancer vaccines, neuro-therapeutics, and cardiovascular therapies are taking off and I am looking forward to helping American Peptide Company customers meet their drug development and manufacturing needs.”
Mr. Shakoori has 25 years of experience in the peptide industry, holding various positions of increasing importance including GMP production chemist, vice-president of GMP manufacturing, and director of sales. Prior to joining American Peptide Company, Shakoori worked in Bachem and PolyPeptide Laboratories.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE